Focal Liver Lesions & LI-RADS
- Focal liver lesions are common, mostly boring, and the whole game is sorting the harmless ones from the dangerous ones.
- The trick is timing: liver imaging is built around watching contrast wash in and out over distinct phases, because the liver has two blood supplies and tumors play favorites.
- Context is king. The same-looking lesion means very different things in a healthy liver versus a cirrhotic one.
- LI-RADS is a structured scoring system used only in patients at risk for hepatocellular carcinoma (HCC) — it puts a number on how worried you should be.
- The two hallmark features of HCC are arterial phase hyperenhancement and later washout. Memorize those two phrases and you're halfway home.
You order a CT for someone's belly pain, and there it is — a little spot on the liver. Now what? Liver lesions are the radiology equivalent of finding a noise in your car: usually it's nothing, occasionally it's everything, and the entire skill is telling those two apart without taking the engine out.
The good news: the liver is unusually cooperative about giving up its secrets, if you know when to take the pictures.
Why the liver is a two-faucet sink
Most organs get blood from one place. The liver is greedy and has two: about three-quarters of its blood arrives slow and steady from the portal vein (draining the gut), and the rest comes fast and pressurized from the hepatic artery. Think of a sink with two faucets — a big lazy one and a small fierce one — pouring into the same basin at slightly different times.
That timing difference is the secret to everything. After we inject IV contrast (best seen on a multiphase abdominal CT or MRI), we snap pictures at set moments:
| Phase | Roughly when | Who lights up |
|---|---|---|
| Arterial | Early, ~20–40 sec | Lesions fed by the artery (many tumors) |
| Portal venous | Later, ~60–80 sec | Normal liver fully enhances |
| Delayed | Minutes later | Shows lingering or washing-out contrast |
Normal liver gets most of its blood from the slow portal faucet, so it glows brightest in the portal venous phase. A tumor that has wired itself to the fast arterial faucet will instead glow early — and then go dark as the normal liver around it catches up. That early glow is arterial phase hyperenhancement, and the later "I'm now darker than the liver around me" is washout. Hold onto those two.
The usual suspects
In a normal liver, most focal lesions are benign and have signature looks.
- Simple cyst — just a bag of water. No enhancement, sharp edges, bright on ultrasound's far side (a clue we call posterior acoustic enhancement). Boring is good.
- Hemangioma — a tangle of blood vessels, the most common solid benign lesion. The classic tell is discontinuous nodular enhancement starting at the edges and filling toward the center over the phases, like ink soaking into a napkin from the rim inward.
- Focal nodular hyperplasia (FNH) — benign overgrowth, often with a central scar. Lights up briskly in the arterial phase but, crucially, does not wash out.
- Adenoma — also benign-ish but the high-maintenance one; it can bleed or rarely turn nasty, so it doesn't get ignored.
A lesion under about a centimeter is often too small to characterize confidently — the scanner just can't resolve enough detail. "Too small to characterize" is a real, respectable thing to say, usually paired with a sensible follow-up rather than panic.
When the liver is sick: enter LI-RADS
Now change the setting. In a patient with chronic liver disease — typically cirrhosis, chronic hepatitis B, or similar risk — a new nodule is guilty until proven innocent, because this is exactly the soil where hepatocellular carcinoma grows.
This is where the Liver Imaging Reporting and Data System (LI-RADS) comes in. It's a standardized framework, endorsed by the American College of Radiology, that applies only to at-risk patients. Using it on a healthy liver is like using a fire alarm to check if your toast is done — wrong tool, wrong question.
LI-RADS assigns a category that translates roughly to "how likely is this HCC?"
| Category | Plain-English meaning |
|---|---|
| LR-1 | Definitely benign |
| LR-2 | Probably benign |
| LR-3 | Intermediate — could go either way |
| LR-4 | Probably HCC |
| LR-5 | Definitely HCC |
| LR-M | Probably or definitely malignant, but not specific for HCC |
The category is built from major features — chiefly arterial phase hyperenhancement, washout, an enhancing capsule, size, and growth over time. (See why we drilled those two enhancement phrases?)
LR-5 carries enough confidence that HCC can often be diagnosed and treated on imaging alone, without a biopsy — one of the rare places in oncology where the picture is the diagnosis.
The traps that get everyone
A liver full of lesions in someone with a known cancer elsewhere is metastases until proven otherwise — and metastatic disease, not HCC, is statistically the most common malignant thing in the liver overall. LI-RADS does not apply here; it's only for the HCC-risk crowd. Match the tool to the patient.
Two more classic snares. First, arterial-only spots that vanish on later phases in a cirrhotic liver are often just quirks of blood flow, not tumor — true HCC usually shows washout too. Second, beware reading too much into a single phase: liver characterization lives or dies on having all the phases, which is why the radiologist gets cranky when only one was ordered.
When a lesion does turn out to be HCC, imaging doesn't just diagnose it — it guides treatment, including image-guided options like tumor ablation for smaller tumors.
The one thing to walk away with
Liver lesions come down to two questions, asked in order: What kind of liver am I looking at? and How does this spot behave as contrast moves through it? Answer those — healthy versus at-risk, then in versus out — and most of the chaos resolves into a small, learnable set of patterns. The fancy scoring systems are just bookkeeping on top of that simple, two-faucet idea.